Physician

Adriana Katz, MD

According to 2025 Medicare claims, Adriana Katz, MD (NPI: 1952355356) practices endocrinology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. Katz uses personal NPI as billing NPI and primary practice location at 07601-3245.

Katz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 473 traditional Medicare patients, billed 5,232 HCPCS/CPT codes, and received $330,143 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 3,395 prescription claims across 489 beneficiaries totaling $821,875 in drug costs, led by Ozempic (Semaglutide). DME data shows 122 claims. Open Payments data shows 18 records totaling $304. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $185,833 to $330,143. Similarly, Part D prescription costs have risen steadily, from $455,397 to $821,875. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $3,234 to $26,645.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	531	1,826	$185,833
2016	566	1,968	$201,009
2017	540	1,910	$192,651
2018	525	1,902	$184,925
2019	510	1,785	$180,033
2020	435	1,598	$149,360
2021	433	2,444	$231,996
2022	460	3,409	$276,214
2023	478	4,021	$293,711
2024	473	5,232	$330,143

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	444	3,255	$455,397
2016	436	3,280	$455,241
2017	442	3,086	$432,673
2018	449	2,973	$429,866
2019	442	2,878	$425,584
2020	414	2,839	$513,561
2021	428	2,871	$584,643
2022	437	2,870	$640,436
2023	454	2,998	$749,142
2024	489	3,395	$821,875

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	353	831	$12,812
2016	327	800	$11,492
2017	237	515	$7,116
2018	235	597	$10,523
2019	246	553	$12,532
2020	158	431	$12,272
2021	181	494	$10,911
2022	257	698	$19,303
2023	206	368	$20,997
2024	30	122	$19,631

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	282	786	$141
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	323	672	$98
99457	Management using the results of remote vital sign monitoring per calendar month, first 20 minutes	137	1,315	$41
99454	Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days	132	1,253	$41
99458	Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes	134	1,040	$33

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	91	4,576	$140,412
Januvia	Sitagliptin Phosphate	105	6,710	$123,288
Trulicity	Dulaglutide	73	3,300	$107,918
Farxiga	Dapagliflozin Propanediol	98	5,620	$105,310
Jardiance	Empagliflozin	60	4,130	$80,201

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	56	$18,853
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	17	40	$737
A4259	Lancets, per box of 100	N	13	26	$42

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	18	$304	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adriana Katz, MD?

Tedicare shows public-source Medicare data for Adriana Katz, MD (NPI 1952355356), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adriana Katz, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adriana Katz, MD?

A separate primary affiliated billing organization is not shown for this profile in the available data.

Does Adriana Katz, MD have Open Payments data?

Adriana Katz, MD has 18 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.